Wednesday, July 8, 2026

Patent intelligence · US

US 10456412

Lipid extraction processes

granted A61KA61K31/20A61K31/225A61K31/23
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 13
Applicant portfolio 175
Patent details — US 10456412
Jurisdiction
US
Status
granted
Grant date
Oct 29, 2019
Expiration
Oct 24, 2039
Claims
11
CPC classes
A61K, A61K31/20, A61K31/225, A61K31/23
View on Google Patents ↗

Quick answer

US 10456412 (Lipid extraction processes) is held by AKER BIOMARINE ANTARCTIC AS. Status: granted. Granted Oct 29, 2019. Expires Oct 24, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
11
CPC classes
A61K, A61K31/20, A61K31/225, A61K31/23, A61K31/683, A61K31/685

More from AKER BIOMARINE ANTARCTIC AS

Related pharmaceutical patents in our USPTO index.

  1. US 12427171

    Krill oil composition enriched in LPC-DHA and LPC-EPA

    Aker BioMarine Human Ingredients AS · Expires Sep 25, 2045

    granted
  2. US 12331293

    Bispecific antisense oligonucleotides for dystrophin exon skipping

    BIOMARIN TECHNOLOGIES B.V. · Expires Jun 12, 2045

    granted
  3. US 12239692

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Expires Feb 27, 2045

    granted
  4. US 12233106

    C-type natriuretic peptide variants to treat skeletal dysplasia in children

    BIOMARIN PHARMACEUTICAL INC. · Expires Feb 20, 2045

    granted
  5. US 12214015

    Use of c-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. · Expires Jan 30, 2045

    granted
  6. US 12194064

    Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids

    Aker BioMarine Human Ingredients AS · Expires Jan 9, 2045

    granted
  7. US 12188058

    Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Expires Jan 2, 2045

    granted
  8. US 12076372

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Expires Aug 29, 2044

    granted

Frequently asked questions

What is US patent 10456412?

US 10456412 (Lipid extraction processes) is held by AKER BIOMARINE ANTARCTIC AS. Status: granted. Granted Oct 29, 2019. Expires Oct 24, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10456412?

AKER BIOMARINE ANTARCTIC AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 175 pharmaceutical patents for this assignee.

When does US 10456412 expire?

Our index shows an expiration date of Oct 24, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.